Buy Cipla, says Rahul Mohindar

Rahul Mohindar of viratechindia.com recommends buying Cipla as the stock may move towards Rs 780-775.

Rahul Mohindar of viratechindia.com told CNBC-TV18, "I would play safe and look at Cipla  and Dr Reddy's Labs . Even at Rs 710 something like Cipla could be bought into. We would be looking at targets more towards Rs 780 or Rs 775. So I still think pharma is positive from an Index perspective."

The company's trailing 12-month (TTM) EPS was at Rs 15.49 per share. (Dec, 2014). The stock's price-to-earnings (P/E) ratio was 45.97. The latest book value of the company is Rs 125.68 per share. At current value, the price-to-book value of the company was 5.67. The dividend yield of the company was 0.28 percent.

Disclosure: Analyst does not personally hold the stocks but may have made recommendation earlier on.

Anda sedang membaca artikel tentang

Buy Cipla, says Rahul Mohindar

Dengan url

https://untukkesehatanda.blogspot.com/2015/03/buy-cipla-says-rahul-mohindar.html?m=0

Anda boleh menyebar luaskannya atau mengcopy paste-nya

Buy Cipla, says Rahul Mohindar

namun jangan lupa untuk meletakkan link

Buy Cipla, says Rahul Mohindar

sebagai sumbernya